Alimera Sciences (NASDAQ: ALIM) is one of 48 public companies in the “Biopharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare Alimera Sciences to similar businesses based on the strength of its institutional ownership, dividends, risk, analyst recommendations, valuation, earnings and profitability.
This table compares Alimera Sciences and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Alimera Sciences Competitors||-13,597.63%||-103.31%||-25.61%|
This is a breakdown of current ratings and recommmendations for Alimera Sciences and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Alimera Sciences Competitors||128||793||1733||59||2.64|
Alimera Sciences presently has a consensus target price of $4.00, suggesting a potential upside of 230.58%. As a group, “Biopharmaceuticals” companies have a potential upside of 16.01%. Given Alimera Sciences’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Alimera Sciences is more favorable than its rivals.
Volatility and Risk
Alimera Sciences has a beta of 2.21, indicating that its stock price is 121% more volatile than the S&P 500. Comparatively, Alimera Sciences’ rivals have a beta of 1.22, indicating that their average stock price is 22% more volatile than the S&P 500.
Insider & Institutional Ownership
36.8% of Alimera Sciences shares are held by institutional investors. Comparatively, 45.2% of shares of all “Biopharmaceuticals” companies are held by institutional investors. 14.7% of Alimera Sciences shares are held by insiders. Comparatively, 15.5% of shares of all “Biopharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares Alimera Sciences and its rivals gross revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Alimera Sciences||$34.33 million||-$33.17 million||-3.90|
|Alimera Sciences Competitors||$563.95 million||$96.15 million||54.26|
Alimera Sciences’ rivals have higher revenue and earnings than Alimera Sciences. Alimera Sciences is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
About Alimera Sciences
Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina. The Company’s product is ILUVIEN, which is developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. In the United States, ILUVIEN is indicated for the treatment of DME in patients who have been treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries, ILUVIEN is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies.
Receive News & Ratings for Alimera Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.